Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide

M Cozzolino, A Galassi, F Conte… - … and clinical risk …, 2017 - Taylor & Francis
Secondary hyperparathyroidism (SHPT), a very frequent, severe, and worsening
complication of chronic kidney disease, is characterized by high serum parathyroid hormone …

Pro: Should phosphate binders be used in chronic kidney disease stage 3–4?

A Bellasi - Nephrology Dialysis Transplantation, 2016 - academic.oup.com
Convincing epidemiological data have repeatedly shown that increased phosphate levels
as well as generous phosphate intakes are associated with unfavourable outcome both in …

Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease

D Russo, A Bellasi, A Pota, L Russo, B Di Iorio - Journal of Nephrology, 2015 - Springer
Background Phosphorus is associated with mortality in patients with chronic kidney disease
(CKD) not on dialysis, possibly through phosphorus-dependent vascular calcification …

[PDF][PDF] Nutrients of cubiu fruits (Solanum sessiliflorum Dunal, Solanaceae) as a function of tissues and ripening stages

MC Andrade Jr, JS Andrade, SS Costa… - Journal of food and …, 2017 - academia.edu
Abstract Cubiu fruits (Solanum sessiliflorum Dunal, Solanaceae) are nutritionally dense.
However, most studies have investigated cubiu nutrients in whole fruits. This study …

New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology

A Bellasi, M Cozzolino, F Malberti, G Cancarini… - Journal of …, 2020 - Springer
Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder;
CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis …

盐酸司维拉姆对慢性肾衰竭维持性血液透析患者高磷血症的影响

周宏久, 冯永民, 贾晓燕, 莫湛宇, 刘华锋 - 中国血液净化, 2015 - cjbp.org.cn
目的评价盐酸司维拉姆治疗慢性肾衰竭维持性血液透析患者高磷血症的临床疗效及安全性.
方法选取广东医学院附属医院2013 年7 月~ 2014 年7 月维持性血液透析患者24 例 …

Interaction between phosphorus and parathyroid hormone in non-dialysis CKD patients under nephrology care

L De Nicola, G Conte, P Chiodini, P D'Angiò… - Journal of …, 2014 - Springer
Background Whether the traditional treatment of chronic kidney disease (CKD)–mineral and
bone disorder is effective in the setting of tertiary nephrology care is an unexplored question …

Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD), coinvolgimento cardiovascolare e prognosi

A Bellasi, M Mangano, A Galassi… - GIORNALE ITALIANO DI …, 2017 - air.unimi.it
Le alterazionidelmetabolismo minerale in corso diinsufficienza renale cronica sono di
frequen te riscontro e si associano a prognosi sfavorevole. Nonostante non sia tuttora chiaro …

Cardiac valve calcification: an immutable pathologic finding in chronic kidney disease?

A Bellasi, A Galassi, S Papagni… - JN. JOURNAL OF …, 2013 - air.unimi.it
Although less frequent than vascular calcification, cardiac valve calcification (CVC) is a
relevant clinical problem affecting about 2%-10% of adults from the general population aged …

Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease

YR Raji, SO Ajayi, AM Adeoye, O Amodu, BO Tayo… - African Health …, 2022 - ajol.info
Background: Excess cardiovascular burden in patients with chronic kidney disease (CKD)
has been attributed to the occurrence of CKD–Mineral Bone Disease (CKD–MBD). This …